Press Releases Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Market Closed - Nasdaq Other stock markets 21:30:00 30/04/2024 BST			5-day change	1st Jan Change
6.92 ^USD	-.--%		-4.42%	-6.49%

04-24	Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	CI
03-29	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	04-29	AQ
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	04-24	AQ
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	02-13	AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	01-09	AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	01-08	AQ
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	01-02	AQ
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	12-28	AQ
Pasithea Therapeutics Announces Results from 2023 Annual Meeting	12-19	AQ
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	12-11	AQ
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	11-29	AQ
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development	11-29	AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 51 Integrin for the Treatment of both Sporadic and Familial ALS	11-10	AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS	11-09	AQ
Pasithea Therapeutics : Investor Presentation	13/10/23	PU
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer	14/09/23	AQ
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference	07/09/23	AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences that shows an increase in 5 integrin expression in ALS human and mouse brain tissue	02/08/23	AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function	01/08/23	AQ
Pasithea Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	20/07/23	PU
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash	20/07/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Press Releases

Filters